Medtronic plc diskutieren

Medtronic plc (NYSE: MDT) had its price target raised by analysts at Barclays PLC from $105.00 to $109.00. They now have an "overweight" rating on the stock.

Medtronic plc (NYSE: MDT) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $105.00 price target on the stock.

I've got a good feeling about Medtronic! They're making some impressive moves in renewable energy and medical tech. That wind power deal in Ireland? Genius! It shows they're not just talking the sustainability talk, but walking the walk. Their financials look solid too, with decent cash flow and consistent dividend growth. The stock's been on a nice upswing lately, outperforming the broader market. Sure, there are challenges, but with their focus on innovation (like that new glucose monitoring system) and smart partnerships, I think they've got room to grow. The current price seems a bit undervalued compared to their potential. It's not without risks, but for a long-term play in healthcare, Medtronic could be just what the doctor ordered!

Medtronic plc (NYSE: MDT) had its price target lowered by analysts at Royal Bank of Canada from $105.00 to $101.00. They now have an "outperform" rating on the stock.

Medtronic plc (NYSE: MDT) had its price target lowered by analysts at Mizuho from $100.00 to $98.00. They now have an "outperform" rating on the stock.

Medtronic plc (NYSE: MDT) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $110.00 price target on the stock.

Medtronic plc (NYSE: MDT) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.

Medtronic PLC (NYSE: MDT) had its price target raised by analysts at Evercore ISI from $103.00 to $106.00. They now have an "outperform" rating on the stock.

Medtronic PLC (NYSE: MDT) had its price target raised by analysts at Citigroup Inc. from $98.00 to $99.00. They now have a "buy" rating on the stock.

Medtronic PLC (NYSE: MDT) had its "overweight" rating re-affirmed by analysts at Morgan Stanley.

Medtronic PLC (NYSE: MDT) had its price target raised by analysts at Mizuho from $98.00 to $100.00. They now have an "outperform" rating on the stock.

Medtronic (NYSE:MDT) had its price target raised by analysts at Sanford C. Bernstein from $97.00 to $98.00. They now have an "outperform" rating on the stock.

Medtronic (NYSE:MDT) had its price target raised by analysts at Wells Fargo & Company from $98.00 to $100.00. They now have an "overweight" rating on the stock.

Medtronic (NYSE:MDT) had its price target raised by analysts at Citigroup Inc. from $99.00 to $101.00. They now have a "buy" rating on the stock.

Medtronic (NYSE:MDT) had its price target raised by analysts at Argus from $105.00 to $115.00. They now have a "buy" rating on the stock.

Medtronic (NYSE:MDT) had its price target raised by analysts at Daiwa Capital Markets from $101.00 to $104.00. They now have a "buy" rating on the stock.

Medtronic (NYSE:MDT) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $82.00 to $81.00. They now have a "sell" rating on the stock.

Medtronic (NYSE:MDT) had its "buy" rating reaffirmed by analysts at Citigroup Inc..

Medtronic (NYSE:MDT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.

Medtronic (NYSE:MDT) had its "outperform" rating reaffirmed by analysts at Sanford C. Bernstein.